Sodium citrate 460 MG Powder for Oral Solution — RxCUI 2671573
RxNorm drug concept · Semantic clinical drug
RxCUI 2671573
Semantic clinical drug · SCD
● Current RxNorm concept 1 FDA product
1 package NDC
Snapshot Jul 14, 2026
What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.
🗂️ Key Facts
RxCUI2671573
Official nameSodium citrate 460 MG Powder for Oral Solution
Concept typeSemantic clinical drug (SCD)
RxNorm statusCurrent RxNorm concept
FDA products mapped1
Package NDCs mapped1
RxNorm release07/06/2026
Snapshot dataJul 14, 2026
🕸️ Concept Web — How Sodium citrate 460 MG Powder for Oral Solution Connects
One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept
Sodium citrate 460 MG Powder for Oral Solution
RxCUI 2671573 Semantic clinical drug · SCD
Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.
-
Ingredients 1
The active substance itself — no strength, form, or brand attached yet.
-
Sodium citrate
56466IN
-
Sodium citrate
-
Brand names 1
The same medicine's trade names. A brand name alone says nothing about strength or form.
-
Emetrol Powder
2671574BN
-
Emetrol Powder
-
Dose forms 9
The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.
-
Sodium citrate Powder for Oral Solution
2671572SCDF -
Sodium citrate Oral Powder Product
2671571SCDG -
Sodium citrate Oral Product
1159676SCDG -
Sodium citrate Powder for Oral Solution [Emetrol Powder]
2671578SBDF -
Emetrol Powder Oral Powder Product
2671577SBDG -
Emetrol Powder Oral Product
2671576SBDG -
Powder for Oral Solution
1540455DF -
Oral Powder Product
1294711DFG - +1 more in this family
-
Sodium citrate Powder for Oral Solution
-
Clinical & branded drugs 3
Ingredient + strength + dose form. These are the concepts real FDA products actually carry.
-
Sodium citrate 460 MG
2671570SCDC -
Sodium citrate 460 MG Powder for Oral Solution [Emetrol Powder]
2671579SBD -
Sodium citrate 460 MG [Emetrol Powder]
2671575SBDC
-
Sodium citrate 460 MG
Showing up to 8 concepts per family — 13 of 14 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.
🔀 Generic ⇄ Brand Crosswalk
The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.
Generic (Clinical) Concepts
-
Sodium citrate 460 MG
SCDC · 2671570 -
Sodium citrate Powder for Oral Solution
SCDF · 2671572 -
Sodium citrate Oral Powder Product
SCDG · 2671571 -
Sodium citrate Oral Product
SCDG · 1159676
Brand-Name Concepts
-
Sodium citrate 460 MG Powder for Oral Solution [Emetrol Powder]
SBD · 2671579 -
Sodium citrate 460 MG [Emetrol Powder]
SBDC · 2671575 -
Sodium citrate Powder for Oral Solution [Emetrol Powder]
SBDF · 2671578 -
Emetrol Powder Oral Powder Product
SBDG · 2671577 -
Emetrol Powder Oral Product
SBDG · 2671576 -
Emetrol Powder
BN · 2671574
📦 FDA Products & Package NDCs
1 product · 1 package NDC
1 package NDC map to RxCUI 2671573 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
| Package NDC | Package | Brand / generic name | Labeler | Marketing start |
|---|---|---|---|---|
| 65197-0203-09 | 6 POWDER, FOR SOLUTION in 1 CARTON (65197-203-09) | Emetrol Powder Non-Drowsy | WellSpring Pharmaceutical Corporation | 2023-12-01 |
Observed labelers:
WellSpring Pharmaceutical Corporation (1)
— this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.
🗃️ Sources & Limits
Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
- A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
- Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
- Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
- Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.
Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.